Back to Search
ANTONIO JIMENO, MD
MD
Medical Oncology Physician
NPI: 1508039991IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
47300(CO)
Education
OTHER
Class of 1998
Research & Publications (20)
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
PMID 19124802·J Clin Oncol·2009
6-review
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
PMID 19029951·Oncogene·2009
7-preclinical
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
PMID 19174553·Mol Cancer Ther·2009
7-preclinical
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
PMID 18955447·J Clin Oncol·2008
3-trial
Assessment of disease named entity recognition on a corpus of annotated sentences.
PMID 18426548·BMC Bioinformatics·2008
8-other
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
PMID 18208793·Clin Transl Oncol·2008
3-trial
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
PMID 17429623·Cancer Chemother Pharmacol·2008
3-trial
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
PMID 18757332·J Clin Oncol·2008
3-trial
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
PMID 18413752·Cancer Res·2008
7-preclinical
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
PMID 18245131·Ann Oncol·2008
3-trial
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
PMID 16425266·Pediatr Blood Cancer·2007
3-trial
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
PMID 17363501·Mol Cancer Ther·2007
4-observational
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
PMID 17342092·Br J Cancer·2007
7-preclinical
Multitargeted therapy: can promiscuity be praised in an era of political correctness?
PMID 16843676·Crit Rev Oncol Hematol·2006
6-review
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
PMID 17172427·Mol Cancer Ther·2006
3-trial
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
PMID 17169762·Clin Transl Oncol·2006
2-rct
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
PMID 17045403·Biochim Biophys Acta·2006
6-review
Atrasentan: a rationally designed targeted therapy for cancer.
PMID 16801993·Drugs Today (Barc)·2006
6-review
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
PMID 16648548·Mol Cancer Ther·2006
6-review
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
PMID 16489045·Cancer Res·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12605 E 16TH AVE
AURORA, CO 80045 - Phone
- (720) 848-0000
Quick Facts
- NPI
- 1508039991
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile